Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 7/20 | 0.50 |
| ▸ | PGK2 | P07205 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616518 | 1.00 | PGK1 (0.50) | PGK1PGK2CYP1A2CYP2A6PTPN1 | |
| SCHEMBL9170574 | 0.92 | PGK1 (0.50) | PGK1PGK2ACP3 | |
| SCHEMBL9169463 | 0.90 | PGK1 (0.48) | PGK1PGK2PTPN1ACP3 | |
| SCHEMBL21585529 | 0.84 | CA12 (0.44) | PGK1PGK2ACP3 | |
| SCHEMBL2867017 | 0.83 | CTRC (0.47) | PGK1PGK2PTPN1ACP3 | |
| SCHEMBL21585534 | 0.82 | CA12 (0.43) | PGK1PGK2PTPN1ACP3 | |
| SCHEMBL148993 | 0.82 | PTPN1 (0.45) | CYP1A2CYP2A6PTPN1 | |
| SCHEMBL5080653 | 0.81 | CYP2A6 (0.42) | PGK1PGK2CYP2A6ACP3 | |
| SCHEMBL11891943 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2A6PTPN1 | |
| SCHEMBL13486393 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2A6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500417-A | ANTIARTHRITIC | THE UPJOHN COMPANY (US) | 1996-03-19 | — | — | US | claimed |
| EP-0661978-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1994007501-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1994-04-14 | — | — | WO | claimed |
| US-20250298333-A1 | POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD | Konica Minolta, Inc. (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11329241-B2 | Exciton-blocking treatments for buffer layers in organic photovoltaics | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-10 | — | — | US | disclosed |
| EP-2484714-B1 | POLYESTER FILM FOR PROTECTION OF BACK SURFACES OF SOLAR CELLS | TOYO BOSEKI (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3083584-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9640689-B2 | Polyester film for the protection of back surfaces of solar cells | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-08 | — | — | US | disclosed |
| EP-0816354-A1 | Process for preparing and stabilisation of aliphatic six-membered cyclic carbonates | BAYER AG (DE) | 1998-01-07 | — | — | EP | disclosed |
| US-5593980-A | ANTIARTHRITIC AGENTS FOR ADMINISTERING | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5500417-A | ANTIARTHRITIC | THE UPJOHN COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0661978-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994007501-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1994-04-14 | — | — | WO | disclosed |
| US-4960841-A | REACTING A PREPOLYMER WITH A MIXTURE OF A DIHALODIPHENYL-SULFONE OR A HALOGENATED AROMATIC COMPOUND AND A SULFIDIZATION AGENT IN A POLAR SOLVENT | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-10-02 | — | — | US | disclosed |
| EP-0023314-B1 | PROCESS FOR PREPARING POLY(ARYLENE SULFIDES) | BAYER AG (DE) | 1983-07-20 | — | — | EP | disclosed |
| US-4331801-A | Process for the preparation of polyarylene sulphides | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0023314-A1 | Process for preparing poly(arylene sulfides) | BAYER AG (DE) | 1981-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | TNNC1, IAPP, TNNI3 | PGK1 2004/4885PGK2 2681/4885CYP1A2 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.